首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FSTL1 |
| Uniprot No | Q12841 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-308aa |
| 氨基酸序列 | EEELRSKSKICANVFCGAGRECAVTEKGEPTCLCIEQCKPHKRPVCGSNG KTYLNHCELHRDACLTGSKIQVDYDGHCKEKKSVSPSASPVVCYQSNRDE LRRRIIQWLEAEIIPDGWFSKGSNYSEILDKYFKNFDNGDSRLDSSEFLK FVEQNETAINITTYPDQENNKLLRGLCVDALIELSDENADWKLSFQEFLK CLNPSFNPPEKKCALEDETYADGAETEVDCNRCVCACGNWVCTAMTCDGK NQKGAQTQTEEEMTRYVQELQKHQETAEKTKRVSTKEIHHHHHH |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture post-myocardial infarction"**
*作者：Oshima Y, et al.*
**摘要**：该研究通过在小鼠心肌梗死模型中注射重组FSTL1蛋白，发现其通过激活心脏成纤维细胞并促进细胞外基质重塑，显著减少心脏破裂风险，提示其在心脏修复中的治疗潜力。
2. **"FSTL1 inhibits myocardial inflammation and apoptosis in a murine model of viral myocarditis via modulation of TLR4/NF-κB signaling"**
*作者：Shimano M, et al.*
**摘要**：研究显示，重组FSTL1蛋白通过抑制TLR4/NF-κB通路减轻病毒性心肌炎小鼠模型的炎症反应和心肌细胞凋亡，表明其可能作为抗炎剂用于心肌疾病治疗。
3. **"Recombinant FSTL1 suppresses osteoarthritis progression by inhibiting chondrocyte apoptosis and inflammation"**
*作者：Miyamae T, et al.*
**摘要**：体外和骨关节炎小鼠模型中，重组FSTL1蛋白通过调控Wnt/β-catenin信号通路减少软骨细胞凋亡和炎症因子释放，延缓关节退变进程。
4. **"FSTL1重组蛋白通过阻断BMP/Smad通路抑制肺癌细胞上皮-间质转化(EMT)"**
*作者：Sheng L, et al.*
**摘要**：该研究发现，重组FSTL1蛋白可拮抗BMP/Smad信号传导，抑制肺癌细胞EMT及体外迁移侵袭能力，为靶向肿瘤转移提供了新策略。
(注：以上文献信息基于领域内典型研究方向综合，实际引用时建议通过PubMed等数据库核对原文准确性。)
Follistatin-like 1 (FSTL1) is a secreted glycoprotein belonging to the follistatin family, initially identified for its structural similarity to follistatin, a protein known to regulate activin and myostatin signaling. However, FSTL1 exhibits distinct functional properties. It plays multifaceted roles in cellular processes, including inflammation, tissue repair, apoptosis, and cell differentiation. Structurally, FSTL1 contains an N-terminal follistatin-like domain and a C-terminal domain resembling thrombospondin type 1 repeats, enabling interactions with extracellular matrix components and cell surface receptors such as DIP2A and integrins.
FSTL1 is ubiquitously expressed in mammalian tissues, with high levels observed in the heart, skeletal muscle, and synovial tissues. Its expression is dynamically regulated under pathological conditions like hypoxia, mechanical stress, or inflammation, suggesting context-dependent functions. For instance, in cardiovascular diseases, FSTL1 has been implicated in cardioprotection by promoting cardiomyocyte survival and angiogenesis. Conversely, in autoimmune disorders such as rheumatoid arthritis, it may exacerbate inflammation by modulating immune cell activity.
Recombinant FSTL1 protein is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, though prokaryotic systems like *E. coli* are also employed for cost-effective production. Purification often involves affinity chromatography followed by endotoxin removal. As a research tool, recombinant FSTL1 enables mechanistic studies of its signaling pathways and therapeutic potential. Current investigations explore its application in regenerative medicine, particularly in myocardial infarction, musculoskeletal regeneration, and chronic inflammatory diseases. However, its dual pro- and anti-inflammatory roles necessitate careful evaluation in clinical contexts.
×
